PETALING JAYA: Pharmaniaga
LifeScience Sdn Bhd, the wholly-owned subsidiary of Pharmaniaga Bhd, has entered into a research collaboration agreement with BioNet-Asia Co Ltd, a Thai-French biotech vaccine company, for the development of a hexavalent vaccine.
Specifically for children, the vaccine is slated to be ready by the end of 2023 and commercialised by 2026.
Already a subscriber? Log in
The Star Festive Promo: Get 35% OFF Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
